GHCM
DNTH icon

Glen Harbor Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Glen Harbor Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$26K Hold
162
– – ﹤0.01% 1282
2019
Q2 		$38K Hold
162
– – ﹤0.01% 1268
2019
Q1 		$43K Hold
162
– – ﹤0.01% 1234
2018
Q4 		$15K Sell
162
-131
-45% -$17.9K ﹤0.01% 1252
2018
Q3 		$56K Hold
293
– – ﹤0.01% 1232
2018
Q2 		$63K Buy
+293
New +$66.1K ﹤0.01% 1198

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Glen Harbor Capital Management's DNTH Position: Q3 2019 in Review

Glen Harbor Capital Management held its Dianthus Therapeutics (DNTH) position steady in Q3 2019 at 162 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #1282.

Glen Harbor Capital Management first reported a position in DNTH in Q2 2018 and has held it in 6 quarters since. The position peaked at $63K in Q2 2018. 72 funds tracked by Wall St. Rank hold DNTH as of Q3 2019.

  • Glen Harbor Capital Management held 162 shares of Dianthus Therapeutics worth $26K as of Q3 2019.
  • Glen Harbor Capital Management left its Dianthus Therapeutics share count unchanged in Q3 2019.
  • Dianthus Therapeutics made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1282 holding.
  • Glen Harbor Capital Management first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Glen Harbor Capital Management's Dianthus Therapeutics position peaked at $63K in Q2 2018.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.